Fluciclovine F-18: all 36 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceRecruitingNCT07569926Phase 4
• Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaRecruitingNCT06613841Early Phase 1
• 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingNCT06103838Phase 2
• Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTRecruitingNCT06062745Phase 1
• 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic RadiosurgeryRecruitingNCT06048094Phase 1
• Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGGRecruitingNCT05555550Early Phase 1
• Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain MetastasisRecruitingNCT05554302Phase 2
• 18F-Fluciclovine PET-MRI in High-grade GliomaRecruitingNCT05553041Early Phase 1
• Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic RadiosurgeryRecruitingNCT04689048Phase 1
• Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedNCT04750473Phase 1Results posted
• Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)CompletedNCT04410367Phase 2Results posted
• Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain MetastasesCompletedNCT04410133Phase 3Results posted
• 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging TherapiesCompletedNCT04158245Phase 2Results posted
• An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate CancerTerminatedNCT04134208Phase 4Results posted
• Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesActive, not recruitingNCT03762759Phase 2Results posted
• Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the BoneCompletedNCT03707184Phase 2Results posted
• Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.TerminatedNCT03423082Phase 4Results posted
• High Resolution PET-MRI Before Prostate Cancer HIFUCompletedNCT03263780Phase 2Results posted
• 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer TreatmentCompletedNCT02680041Phase 3Results posted
• FACBC for Recurrent Prostate CancerCompletedNCT01808222Phase 2Results posted
• FACBC Outcomes for Post ProstatectomyCompletedNCT01666808Phase 2/3Results posted
• Anti-3-[18F]FACBC Imaging of Parathyroid AdenomasCompletedNCT01574287Not applicableResults posted
• GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate CancerTerminatedNCT01176513Phase 2Results posted
• FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate CancerTerminatedNCT00917865Phase 2Results posted
• Imaging Brain Tumors With FACBC and MethionineCompletedNCT00597246Not applicableResults posted
• FACBC PET/CT for Recurrent Prostate CancerCompletedNCT00562315Phase 2Results posted
• Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PETActive, not recruitingNCT05722925Phase 4
• 18F-Fluciclovine PET/CT in the Assessment of Pancreatic TransplantsCompletedNCT04852523Early Phase 1
• Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With GliomaCompletedNCT04114370Early Phase 1
• [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )CompletedNCT03990285Phase 1
• 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation NecrosisCompletedNCT03930173Early Phase 1
• 18F-Fluciclovine PET and Multiparametric MR ImagingWithdrawnNCT03925675Phase 2
• Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After SurgeryCompletedNCT03515577Phase 2
• Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.Status unknownNCT03349463Phase 4
• FACBC for Head and Neck CancersWithdrawnNCT01933269Early Phase 1
• Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the BreastCompletedNCT01659645Early Phase 1

← Fluciclovine F-18 overview